<bill session="107" type="h" number="3966" updated="2013-07-14T18:58:21-04:00">
  <state datetime="2002-03-14">REFERRED</state>
  <status>
    <introduced datetime="2002-03-14"/>
  </status>
  <introduced datetime="2002-03-14"/>
  <titles>
    <title as="introduced" type="short">Genomic Science and Technology Innovation Act of 2002</title>
    <title as="introduced" type="official">To direct the Director of the Office of Science and Technology Policy to conduct a study of the impact of Federal policies on the innovation process for genomic technologies, and for other purposes.</title>
  </titles>
  <sponsor id="400528"/>
  <cosponsors>
    <cosponsor id="400204" joined="2002-06-18"/>
    <cosponsor id="400380" joined="2002-05-09"/>
    <cosponsor id="400427" joined="2002-03-14"/>
  </cosponsors>
  <actions>
    <action datetime="2002-03-14">
      <text>Sponsor introductory remarks on measure.</text>
      <reference ref="CR E353-355"/>
    </action>
    <action state="REFERRED" datetime="2002-03-14">
      <text>Referred to the Committee on Science, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2002-03-14">
      <text>Referred to House Science</text>
    </action>
    <action datetime="2002-03-14">
      <text>Referred to House Judiciary</text>
    </action>
    <action datetime="2002-03-22">
      <text>Referred to the Subcommittee on Environment, Technology, and Standards.</text>
      <committee name="House Science"/>
    </action>
    <action datetime="2002-03-22">
      <text>Referred to the Subcommittee on Research.</text>
      <committee name="House Science"/>
    </action>
    <action datetime="2002-05-06">
      <text>Referred to the Subcommittee on Courts, the Internet, and Intellectual Property.</text>
      <committee name="House Judiciary"/>
    </action>
  </actions>
  <committees>
    <committee code="HSSY" name="House Science" activity="Referral, In Committee"/>
    <committee activity="Referral" code="HSSY19" subcommittee="Environment, Technology, and Standards" name="House Science"/>
    <committee activity="Referral" code="HSSY14" subcommittee="Research" name="House Science"/>
    <committee code="HSJU" name="House Judiciary" activity="Referral, In Committee"/>
    <committee activity="Referral" code="HSJU03" subcommittee="Courts, the Internet, and Intellectual Property" name="House Judiciary"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Science, technology, communications"/>
    <term name="Capital investments"/>
    <term name="Commercialization"/>
    <term name="Congress"/>
    <term name="Congressional reporting requirements"/>
    <term name="Data banks"/>
    <term name="Federal advisory bodies"/>
    <term name="Finance and financial sector"/>
    <term name="Gene therapy"/>
    <term name="Genetic research"/>
    <term name="Government operations and politics"/>
    <term name="Health"/>
    <term name="Human genetics"/>
    <term name="Intellectual property"/>
    <term name="Legislation"/>
    <term name="Medical tests"/>
    <term name="Patents"/>
    <term name="Policy sciences"/>
    <term name="Regulatory impact statements"/>
    <term name="Research and development"/>
    <term name="Technological innovations"/>
  </subjects>
  <amendments/>
  <summary>3/14/2002--Introduced.
Genomic Science and Technology Innovation Act of 2002 - Requires the Director of the Office of Science and Technology Policy to conduct, or contract with the National Academy of Sciences to conduct, a study that assesses the impact of Federal policies, including intellectual property policies, on the innovation process for genomic technologies.Requires such study to: (1) identify and quantify the effects of innovation policy on genomic science and technology innovation; (2) consider alternative levels of intellectual property protection genomic materials may receive and the likely impact on each element of the innovation pipeline; and (3) assess the net impact of Federal innovative policies.</summary>
</bill>
